Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer

被引：0
|
作者：
Xia Xu
Fei Deng
Mengmeng Lv
Binhui Ren
Wenwen Guo
Xiaoxiang Chen
机构：
[1] Department of Chemotherapy,
[2] Jiangsu Cancer Hospital,undefined
[3] Department of Gynecologic Oncology,undefined
[4] Jiangsu Cancer Hospital,undefined
[5] Department of Thoracic Oncology,undefined
[6] Jiangsu Cancer Hospital,undefined
[7] The Second Affiliated Hospital of Nanjing Medical University,undefined
来源：
Journal of Ovarian Research | / 9卷
关键词：
High grade serous ovarian cancer; CA-125; Ascites; Primary debulking surgery; Interval debulking surgery;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma
    Coghlan, Edwina
    Meniawy, Tarek M.
    Munro, Aime
    Bulsara, Max
    Stewart, Colin J. R.
    Tan, Adeline
    Koay, M. H. Eleanor
    MaGee, Daniel
    Codde, Jim
    Tan, Jason
    Salfinger, Stuart G.
    Mohan, Ganendra R.
    Leung, Yee
    Nichols, Cassandra B.
    Cohen, Paul A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (04) : 708 - 713
  • [42] Acquired chemotherapy resistance in high-grade serous ovarian cancer patients.
    Christie, Elizabeth L.
    Beach, Jessica
    Etemadmoghadam, Dariush
    Garsed, Dale
    Patch, Ann-Marie
    Fereday, Sian
    Pattnaik, Swetansu
    Brady, Samuel
    Bild, Andrea
    Bowtell, David D. L.
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 20 - 20
  • [43] Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab.
    Gourley, Charlie
    McCavigan, Andrena
    Perren, Timothy
    Paul, James
    Michie, Caroline Ogilvie
    Churchman, Michael
    Williams, Alistair
    McCluggage, W. Glenn
    Parmar, Mahesh
    Kaplan, Richard S.
    Hill, Laura A.
    Haifpenny, Iris A.
    O'Brien, Earnonn J.
    Raji, Olaide
    Deharo, Steve
    Davison, Timothy
    Johnston, Patrick
    Keating, Katherine E.
    Harkin, D. Paul
    Kennedy, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer
    Vanguri, Rami
    Benhamida, Jamal
    Young, Jonathan H.
    Li, Yanyun
    Zivanovic, Oliver
    Chi, Dennis
    Snyder, Alexandra
    Hollmann, Travis J.
    Mager, Katherine L.
    GYNECOLOGIC ONCOLOGY REPORTS, 2022, 39
  • [45] Tumor regression grading after neoadjuvant chemotherapy predicts long-term outcome of stage IIIC epithelial ovarian cancer.
    Zhou, Mingyi
    Li, Liankun
    Wang, Xiaobin
    Wang, Chunyan
    Wang, Danbo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] Ultrasound characteristics of early-stage high-grade serous ovarian cancer
    Suh-Burgmann, Elizabeth
    Brasic, Natasha
    Jha, Priyanka
    Hung, Yun-Yi
    Goldstein, Ruth B.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2021, 225 (04) : 409.e1 - 409.e8
  • [47] Lipid Alterations in Early-Stage High-Grade Serous Ovarian Cancer
    Iurova, M. V.
    Chagovets, V. V.
    Pavlovich, S. V.
    Starodubtseva, N. L.
    Khabas, G. N.
    Chingin, K. S.
    Tokareva, A. O.
    Sukhikh, G. T.
    Frankevich, V. E.
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
  • [48] Disparities in treatment modalities and survival among older patients with high-grade serous ovarian cancer
    Yan Cai
    Tong Shu
    Hong Zheng
    BMC Women's Health, 24
  • [49] Disparities in treatment modalities and survival among older patients with high-grade serous ovarian cancer
    Cai, Yan
    Shu, Tong
    Zheng, Hong
    BMC WOMENS HEALTH, 2024, 24 (01)
  • [50] Spatial patterns of immune cell states are associated with poor response to neoadjuvant chemotherapy in high-grade serous ovarian cancer
    Niemiec, Iga
    Kahelin, Essi
    Liang, Zhihan
    Erkan, Erdogan P.
    Vaharautio, Anna
    Virtanen, Anni
    Farkkila, Anniina
    CANCER RESEARCH, 2024, 84 (05)
12345